http://affinitysetters.com/siteindex.htm
Hematide is in a Phase III Renton led Onyx for nearlty15 years, stepping down in February 2008 as CEO, chairman and a membeer of Onyx’s board. At the he helped negotiate a development and commercialization partnership with that resulted inthe anti-canceer drug Nexavar. Nexavar tablets, whicuh cost about $5,000 a month in the Unites States and areapproaching $1 billion in annualk sales, are approved in more than 80 countries to treaf kidney cancer and 70-plus countries for liver cancer. Priofr to joining Onyx, Rento n was president and COO of which acquired Cetusin 1991. Renton had been presidenf of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987.
Rentoh also serves on the boardssof , Cepheid and the Special Olympics of Northernh California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment